Permitted daily exposure from preclinical studies of Ginkgo biloba L. dry extract

Abstract Resolution 658/2022 of the Brazilian Regulatory Agency requires the determination of the permitted daily exposure (PDE) of pharmaceutical agents. Ginkgo biloba L. is used therapeutically to treat memory deficits and other brain diseases. However, published results indicate that more studies are needed to confirm the safety of Ginkgo biloba. This study aimed to evaluate the dry extract of Ginkgo biloba L. leaves PDE as an ingredient in an oral pharmaceutical product in preclinical studies using mice. Acute oral toxicity and repeated dose experiments were performed based on OECD guidelines, as well as genotoxicity tests. The results indicate that Ginkgo biloba L. has low acute toxicity, no liver toxicity, and does not alter blood glucose levels. No changes in weight gain were observed, but food intake decreased in males during the first week of treatment at the highest dose. Hematological parameters were not altered in males, whereas females presented lower leukocyte and lymphocyte counts and higher neutrophil counts at the highest dose. The lipid profile was not altered in males, whereas total cholesterol was increased in females. The estimated PDE was 0.1 mg/day and, when related to the maximum residual concentration, indicates that the cleaning process used is safe and does not require reassessment.

Quality control strategy of traditional Chinese medicine based on pharmaceutical product lifecycle management / 中国中药杂志

Quality control is pivotal in the research and development of traditional Chinese medicine, whose connotation is not limi-ted to the qualitative or quantitative detection of an indicator component, but extends to the establishment of a whole process quality control system from the perspective of pharmaceutical product lifecycle management. This study discussed the quality control strategy of Chinese medicine based on the concept of pharmaceutical product lifecycle management, and proposed the following suggestions:(1) to focus on the "holistic view" and "phased" characteristics of quality control and strengthen the establishment of quality control strategy based on top-level design;(2) to strengthen the research on quality control of Chinese medicine based on quality risk management, focus on the correlations of quality control indicators with the safety and effectiveness of traditional Chinese medicine, and establish a quality evaluation system consistent with the characteristics of traditional Chinese medicine;(3) to consider the characteristics of different registration classifications in the establishment of quality control strategy;(4) to highlight the quality correlation research, strengthen the quality transfer research, ensure the quality traceability, and establish a sound quality management system;(5) to strengthen the quality research on marketed drugs to achieve dynamic quality improvement.

A Report on the Distribution of "Lethal Dose/Pharmaceutical Product Strength” in High-Risk Drugs / 医薬品情報学

Objective: This study assessed the distribution of "lethal dose/pharmaceutical product strength" in high-risk drugs.Methods: In 707 pharmaceutical products (312 ingredients) that had been defined as high-risk drugs in Japan, we collected acute toxicity information from these products on single dose toxicity studies conducted in mice, including median lethal dose (LD50) and approximate lethal dose (aLD). The LD50 and aLD were then divided by the strength (quantity of active ingredients) of the pharmaceutical product, after which the LD50or aLD values having an inequality sign was excluded.Results: We collected data on the acute lethal dose of 707 products (312 ingredients) from high-risk drugs. Data with an inequality sign, which was 143 of 495 products (28.9%) in tablets and capsules, then 43 of 212 items (20.3%) in injections, were excluded from the analysis. As observed, median (Q1, Q3) of "LD50/pharmaceutical product strength" and "aLD/pharmaceutical product strength" for tablets or capsules was 36.8 tablet/kg (11.5 tablet/kg, 144 tablet/kg) and 16.7 tablet/kg (6.9 tablet/kg, 65 tablet/kg), respectively. However, median (Q1, Q3) of "LD50/pharmaceutical product strength" and "aLD/pharmaceutical product strength" for injections were 1.3 bottle/kg (0.6 bottle/kg, 4.7 bottle/kg) and 0.8 bottle/kg (0.4 bottle/kg, 15 bottle/kg), respectively. In both cases, injections were distributed at a lower value than oral products.Conclusion: From this study, the distribution of "lethal dose/pharmaceutical product strength" in high-risk drugs was clarified. This information will therefore help pharmacists assess risks associated with individual pharmaceutical products.

Mapeamento dos domínios da ANVISA para o padrão ISO IDMP / Mapping of ANVISA domains to the ISO IDMP standard / Mapeo de dominios de ANVISA al estándar ISO IDMP

Objetivo: Apresentar o mapeamento entre vocabulários controlados da Agência Nacional de Vigilância Sanitária (ANVISA) para listas do European Directorate for the Quality of Medicines and Healthcare (EDQM). Método: O mapeamento obedeceu aos princípios da ABNT NBR ISO 12300. Resultados: Foram mapeadas as listas: Via de Administração, Forma Farmacêutica e Embalagem. 47% dos mapeamentos foram classificados com grau de equivalência 4, onde o conceito fonte foi mais restrito com mais significado específico que o conceito/termo alvo. Conclusão: Entende-se que este estudo fornece subsídios para a ANVISA prosseguir no trabalho de harmonização das listas locais com o padrão IDMP.

Objective: To present the mapping between controlled Brazilian Health Regulatory Agency (ANVISA) vocabularies for European Directorate for the Quality of Medicines and Healthcare (EDQM) lists. Method: The mapping followed the principles described in the ABNT NBR ISO 12300. Results: Terms of three lists were mapped: Routes of Administration, Pharmaceutical Dose Forms and Packaging. Almost half of the mappings were classified with equivalence grade 4 meaning that the source concept was more restricted with more specific meaning than the target concept / term. Conclusion: This work provides the necessary subsidies for ANVISA to proceed with the work of harmonizing local lists with the IDMP standard.

Objetivo: Presentar el mapeo entre vocabularios controlados de Agencia Nacional de Vigilancia Sanitaria (ANVISA) para listas European Directorate for the Quality of Medicines and Healthcare (EDQM). Método: El mapeo siguió los principios descritos en lo estándar ABNT NBR ISO 12300. Resultados: Se mapearon los términos de las listas: Vía de administración, Forma farmacéutica y Embalajes. La mayoría se clasificaron como grado de equivalencia 4, donde el concepto fuente era más restringido con un significado más específico que el concepto/término objetivo. Conclusión: Se entiende que este estudio proporciona subsidios para ANVISA continúe el trabajo de armonizar las listas locales con el estándar IDMP.

Two Manganese Peroxidases and a Laccase of Trametes polyzona KU-RNW027 with Novel Properties for Dye and Pharmaceutical Product Degradation in Redox Mediator-Free System

Two manganese peroxidases (MnPs), MnP1 and MnP2, and a laccase, Lac1, were purified from Trametes polyzona KU-RNW027. Both MnPs showed high stability in organic solvents which triggered their activities. Metal ions activated both MnPs at certain concentrations. The two MnPs and Lac1, played important roles in dye degradation and pharmaceutical products deactivation in a redox mediator-free system. They completely degraded Remazol brilliant blue (25 mg/L) in 10–30 min and showed high degradation activities to Remazol navy blue and Remazol brilliant yellow, while Lac1 could remove 75% of Remazol red. These three purified enzymes effectively deactivated tetracycline, doxycycline, amoxicillin, and ciprofloxacin. Optimal reaction conditions were 50 °C and pH 4.5. The two MnPs were activated by organic solvents and metal ions, indicating the efficacy of using T. polyzona KU-RNW027 for bioremediation of aromatic compounds in environments polluted with organic solvents and metal ions with no need for redox mediator supplements.

Toxicity of the goji berry fruit associated with artificial excipients and dried without additives / Toxicidade do fruto goji berry associado a excipientes artificiais e desidratado sem aditivos

The aim of this study was to evaluate the cytotoxic and genotoxic potential of goji berry fruit-based pharmaceutical powders obtained from three pharmaceutical laboratories. The product A was tested at concentrations of 0.012; 0.025 and 0.05 g mL-1, and B and C at concentrations 0.02; 0.04 and 0.08 g mL-1. It was also evaluated the tea of the dried goji berry fruit (non-additives) in the concentrations 0.035; 0.07 and 0.14 g mL-1 for comparison to the results obtained with powdered goji berry. Tea concentrations in the two exposure times did not cause inhibition of cell division nor cellular alterations to meristem tissues. For the industrialized goji products, all concentrations analyzed caused significant antiproliferative effect to the tissues evaluated at the shortest time of analysis. There were no significant cellular changes in tissues exposed to industrialized goji. Therefore, under the conditions of analysis, goji berry powder, at the three concentrations evaluated, was cytotoxic to root meristems.

Objetivou-se na presente pesquisa avaliar, em células meristemáticas de raízes de A. cepa, nos tempos de exposição 24 e 48 horas, o potencial citotóxico e genotóxico de produtos farmacêuticos do fruto goji berry em pó, provenientes de três laboratórios farmacêuticos. O produto A foi avaliado nas concentrações 0,012; 0,025 e 0,05 g mL-1, e B e C nas concentrações 0,02; 0,04 e 0,08 g mL-1. Avaliou-se também o chá do fruto seco de goji (não aditivado), nas concentrações 0,035; 0,07 e 0,14 g mL-1, para comparação com os resultados obtidos do fruto em pó. Verificou-se que o chá nas concentrações avaliadas, nos dois tempos de exposição estabelecidos, não ocasionaram inibição da divisão celular e nem alterações celulares aos meristemas de raízes. Para os goji industrializados, todas as concentrações analisadas causaram efeito antiproliferativo significativo aos tecidos avaliados logo no menor tempo de análise considerado. Nenhum dos produtos industrializados causou número significativo de alterações aos meristemas analisados. Assim, os goji em pó foram citotóxicos ao bioensaio utilizado por terem acarretado relevante instabilidade genética aos meristemas de raízes.

Validation of high performance liquid chromatographic and spectrophotometric methods for the determination of the antiparkinson agent pramipexole dihydrochloride monohydrate in pharmaceutical products

abstract The antiparkinson agent pramipexole dihydrochloride monohydrate was quantified in pharmaceutical products by high performance liquid chromatography (HPLC) and derivative spectrophotometry. The first method was based on HPLC using tamsulosin HCl as an internal standard. In this method, chromatographic separation was achieved using a LiChrospher 60 RP column at 25°C, with a flow rate of 1.0 mL/min at 263 nm. The eluent comprised 0.01 mol/L ammonium acetate (pH 4.4) and acetonitrile (35:65 by volume). The linearity range was found to be 10.0-30.0 µg/mL with a mean recovery of 100.5 ± 1.10. The limit of detection (8 ng/mL) and limit of quantification (50 ng/mL) were calculated. In the second method, the first derivative spectrophotometric technique for the determination of pramipexole dihydrochloride monohydrate was performed by measuring the amplitude at 249 and 280 nm. In the first derivative technique, the absorbance and concentration plot was rectilinear over the 5.0-35.0 µg/mL range with a lower detection limit of 1.5 ng/mL and quantification limit of 4.5 ng/mL. The typical excipients included in the pharmaceutical product do not interfere with the selectivity of either method. The developed methods were validated for robustness, selectivity, specificity, linearity, precision, and accuracy as per the ICH and FDA guidelines (ICH Q2B, 1996; FDA,2000). In conclusion, the developed methods were successful in determining the quantity of the antiparkinson agent pramipexole dihydrochloride monohydrate in pharmaceutical products. The RSD values for the pharmaceutical product used in this study were found to be 0.97% for the HPLC method and 0.00% for the first derivative spectrophotometric method.

resumo O fármaco antiparkinsoniano, dicloridrato de pramipexol monoidratado, foi quantificado no produto farmacêutico por cromatografia líquida de alta eficiência (CLAE) e espectrofotometria derivada. No primeiro método baseado na CLAE, o cloridrato de tansulosina foi usado como padrão interno. Nesse método, a separação cromatográfica foi realizada usando uma coluna Lichrosper 60 RP a 25 °C e acetato de amônio 0,01 mol/L (pH:4.4): acetonitrila (35:65 em volume) como eluente com fluxo de 1,0 mL /min a 263 nm. A faixa de linearidade foi de 10.0-30.0 µg/mL com média da recuperação 100.5 ± 1.10. O limite de detecção (8 ng/mL) e o limite de quantificação (50 ng/mL) foram calculados. Por outro lado, a primeira técnica de espectrofotometria derivada para a determinação de dicloridrato de pramipexol monoidratado foi realizada através da medida da amplitude a 249 e 280 nm. Na técnia da primeira derivada, a absorvância e a plotagem da concentração foi retilínea na faixa de 5.0-35.0 µg/mL com limite inferior de detecção de 1.5 ng/mL e limite de quantificação de 4.5 ng/mL. Os excipientes típicos incluídos no produto farmacêutico não interferem com a seletividade dos métodos. Os métodos desenvolvidos foram validados quanto à robustez, seletividade, especificidade, linearidade, precisão e exatidão de acordo com as diretrizes do ICH e FDA (ICH Q2B,1996; FDA,2000). Concluindo, os métodos propostos foram aplicados com sucesso para a determinação quantitativa do agente antiparkinsoniano dicloridrato de pramipexol monoidrato em produtos farmacêuticos. Os valores de RSD para o produto farmacêutico utilizado neste estudo foi 0.97% para a CLAE e 0.00% para o método de espectrofotometria de primeira derivada.

Comparison between UV and HPLC methods in the dosage of pharmaceutical products containing a mixture of 2 components amoxicillin and clavulanic acid

UV - spectrophotometric (UV) and high performance liquid chromatographic methods (HPLC) were described in determining amoxicillin and clavulanic acid in pharmaceutical preparations. Spectrophotometrically, amoxicillin was determined by measuring the absorbance values at 320 nm in buffer-CuS04 solution (pH 5.2) for amoxicillin and at 313 nm in imidazol solution (pH 6.8) for clavulanic acid. Beer's Law was obeyed in range 12 - 32mg. ml-1 for amoxicillin and 12 - 22 mg. ml-1 for clavulanic acid. The simultaneous HPLC method depended upon using a reserved phase RP18 column at ambient temperature with a mobile phase consisting of methanol - phosphate solution pH 4.4 (4:96) at a flow rate 1ml.min-1. Quantitation was achieved by UV detection at 220 nm. Calibration curve was linear over the concentration range 50-150 mg. ml-1 for amoxicillin and 15-35 mg. ml-1 for clavulanic acid. Both spectrophotometry and HPLC method showed good linear correlation, precision and accuracy. The obtained results from spectrophotometry and HPLC method showed no significant difference. Both methods were successfully applied to the assay of commercial tablets. The procedures were rapid, simple and suitable for quality control applications

The Tactics of Brand Positioning of Pharmaceutical Products / 中国药房

OBJECTIVE:To provide information about the brand positioning of pharmaceutical products for reference of Chinese pharmaceutical business.METHODS:We overviewed the implication and foundation of brand fixed position of phar?maceutical products and put forward the tactics of brand positioning of pharmaceutical products.RESULTS&CONCLU?SION:Under the conditions of sectionalized market and individulized consumption,nowadays,the existence and development of an enterprise directly depend on the success of brand positioning of its pharmaceutical products.